Product Description
Ketotifen is a type of asthma medication which, when taken every day and used along with other antiasthma medications, may reduce the frequency, severity, and duration of asthma symptoms or attacks in children. It may also lead to a reduction in daily requirements of other antiasthma medications. Ketotifen is not effective for the prevention or treatment of acute asthma attacks. Ketotifen works by inhibiting certain substances in the body that are known to cause inflammation and symptoms of asthma.
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Ophthalmic
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bausch & Lomb
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Italy, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Conjunctivitis, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT05591755 | P3 |
Completed |
Conjunctivitis, Allergic |
2023-08-09 |
38% |
2024-06-12 |
|
| KET-001 | P3 |
Completed |
Conjunctivitis, Allergic |
2024-10-21 |
2025-05-02 |
Treatments |
|
| NCT05579730 | P3 |
Completed |
Conjunctivitis, Allergic |
2023-07-22 |
38% |
2025-02-15 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/23/2024 |
News Article |
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024 |
|
08/06/2024 |
News Article |
The Relief Products® Unveils Innovative Dual Relief Delivery System for Eye Health Care |
|
07/25/2024 |
News Article |
OCuSOFT® Introduces NEW OCuSOFT® Retaine® Allergy Artificial Tears for Eye Allergy Itch Relief |
|
01/17/2024 |
News Article |
2024 BrandSpark Most Trusted Awards Winners Announced for Consumer Products, Retail and Services Brands in the 11th Annual Edition |